Subscribe for great stories in your community!
Last year was a big one for Philadelphia area CEOs. Ten of the top twelve highest earners saw an increase in salary over 2022, write…
Conshohocken’s Madrigal Pharmaceuticals, saw third-quarter sales soar for its NASH treatment, Rezdiffra, writes John George for the Philadelphia Business Journal.
With revenue reaching…
Conshohocken-based Madrigal Pharmaceuticals generated $14.6 million in sales from Rezdiffra, its first and flagship product, during the second quarter of 2024, writes John…
In the less than two months since becoming the first drug developer to receive Food and Drug Administration clearance for a NASH treatment, Madrigal Pharmaceuticals…
Madrigal Pharmaceuticals has been given Food and Drug Administration market clearance for its experimental treatment for NASH, a fatty liver disease that causes inflammation of…
Conshohocken-based Madrigal Pharmaceuticals is in a flurry of activity as it prepares for the potential launch of its NASH drug candidate, writes John George…
Conshohocken-based Madrigal Pharmaceuticals plans to raise $500 million while anticipating FDA approval of a groundbreaking therapy, writes John George for the Philadelphia Business Journal…
Conshohocken biopharmaceutical company Madrigal Pharmaceuticals has named Bill Sibold as the new CEO taking over from Dr. Paul Friedman.
He has also joined the company…
Currently there is no U.S. Food and Drug Administration-approved medicine for nonalcoholic steatohepatitis, also referred to as NASH.
NASH is a fatty liver…
One Montgomery County company found its place on the list of seven best-paying biopharma companies in the nation where workers can take home over…
Conshohocken-based Madrigal Pharmaceuticals saw its shares leap in value after the company reported additional positive late-stage clinical trial data for its experimental non…
Madrigal Pharmaceuticals Inc., a Montgomery County biopharmaceutical company, is seeking to raise $125 million through a common stock offering that began earlier this week. The…
Fort Washington’s Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular…
Fort Washington’s Madrigal Pharmaceuticals has procured $3.4 million in debt financing, according to a filing with the Securities and Exchange Commission, writes John…
Before we send you to this site, please subscribe to our daily newsletter.
